{"nctId":"NCT00604279","briefTitle":"A Comparative Study of Paliperidone Palmitate and Risperidone Long Acting Injection (LAI) in Participants With Schizophrenia","startDateStruct":{"date":"2008-01"},"conditions":["Schizophrenia"],"count":452,"armGroups":[{"label":"Paliperidone palmitate","type":"EXPERIMENTAL","interventionNames":["Drug: Paliperidone palmitate (R092670)"]},{"label":"Risperidone long acting injection (LAI)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Risperidone"]}],"interventions":[{"name":"Paliperidone palmitate (R092670)","otherNames":[]},{"name":"Risperidone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Participants who meet diagnostic criteria for schizophrenia according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (disorganized type \\[295.10\\], catatonic type \\[295.20\\], paranoid type \\[295.30\\], residual type \\[295.60\\], or undifferentiated type \\[295.90\\]) for at least 1 year before screening and prior medical records, written documentation, or verbal information obtained from previous psychiatric providers obtained by the investigator must be consistent with the diagnosis of schizophrenia\n* A total Positive and Negative Syndrome Scale (PANSS) score between 60 and 120, inclusive, at screening and baseline\n* Body mass index (BMI) of equal to or greater than 17.0 kilogram per meter square (kg/m\\^2)\n* Female participants must be postmenopausal for at least 2 years, surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control before study entry and throughout the study\n* Be capable of self-administering study medication (applies to oral supplementation) or have assistance with study medication administration consistently available throughout the first 4 weeks of the study Exclusion Criteria:\n* A primary, active DSM-IV diagnosis on Axis I other than schizophrenia\n* A decrease of at least 25 percent in the total PANSS score between screening and baseline\n* Participants who have previously participated in this study\n* A DSM-IV diagnosis of active substance dependence within 3 months before screening (nicotine and caffeine are not exclusionary)\n* History of treatment resistance as defined by failure to respond to 2 adequate treatments with different antipsychotic medications (an adequate treatment is defined as a minimum of 6 weeks at maximum tolerated dosage)","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Positive and Negative Syndrome Scale (PANSS) Total Score at Day 92 or Early Withdrawal","description":"The PANSS provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 (absent) to 210 (extreme psychopathology). Higher change scores indicate worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":"11.95"},{"groupId":"OG001","value":"84.4","spread":"12.69"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-23.6","spread":"16.28"},{"groupId":"OG001","value":"-26.9","spread":"15.43"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Personal and Social Performance (PSP) Score at Day 92 or Early Withdrawal","description":"This PSP assesses the degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The score ranges from 1 to 100, divided into 10 equal intervals to rate the degree of difficulty (1, absent to 4, very severe) in each of the 4 domains. Based on the four domains there will be one total score. Participants with a score of 71 to 100 have a mild degree of difficulty; from 31 to 70, varying degrees of disability; \\<= 30, functioning so poorly as to require intensive supervision.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47.8","spread":"12.42"},{"groupId":"OG001","value":"45.3","spread":"11.29"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":"14.76"},{"groupId":"OG001","value":"18.6","spread":"13.92"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Clinical Global Impression-Severity (CGI-S) Score at Day 92 or Early Withdrawal","description":"The CGI-S rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to \"Normal, not at all ill\" and a rating of 7 is equivalent to \"Among the most extremely ill participants\". Higher change scores indicate worsening.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.9","spread":"0.82"},{"groupId":"OG001","value":"5.0","spread":"0.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"1.24"},{"groupId":"OG001","value":"-1.7","spread":"1.16"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in the Sleep Visual Analog Scale (VAS) Score at Day 92 or Early Withdrawal","description":"The self-administered sleep VAS scale (0-100 millimeter \\[mm\\]) rates quality of sleep (QoS) and daytime drowsiness (DD). Participants indicate mark on the scale to represent how well they have slept in the previous 7 days, score ranges from 0 mm (very badly) to 100 mm (very well); and how often they have felt drowsy within the previous 7 days, from 0 mm (not at all) to 100 mm (all the time).","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.1","spread":"25.40"},{"groupId":"OG001","value":"66.6","spread":"24.22"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","spread":"26.95"},{"groupId":"OG001","value":"10.0","spread":"26.18"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"29.9","spread":"25.25"},{"groupId":"OG001","value":"29.6","spread":"23.50"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.1","spread":"27.26"},{"groupId":"OG001","value":"-4.9","spread":"24.12"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Who Responded to PANSS Total Score at Day 92 or Early Withdrawal","description":"A responder is defined as a participant who improved from baseline in the PANSS total score by 30 percent or more.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"70.7","spread":"25.40"},{"groupId":"OG001","value":"78.4","spread":"24.22"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":229},"commonTop":["Akathisia","Insomnia","Tremor","Restlessness","Upper respiratory tract infection"]}}}